Eckert & Ziegler Strahlen und Medizintechnik AG

ots Ad hoc-Service: Eckert & Ziegler AG Eckert & Ziegler Awarded CE Approval for New Prostate Cancer Treatment

The sender is solely responsible for the contents of this announcement. ----------------------------------------------------- Berlin (ots Ad hoc-Service) - Eckert & Ziegler Strahlen- und Medizintechnik AG, Berlin (Securities ID 565970), a leading manufacturer of innovative, radioactive components for the treatment of cancer and restenosis, has received European market CE approval for palladium seeds as low-radiation implants for the treatment of prostate cancer. Palladium seeds are especially used for treating prostate tumors in advanced stages. Delivery to a leading international medical supply company is to begin in the 4th quarter. Because of the treatment's high success rate, market volume will increase to about US-$ 50 million in Europe and some US-$ 250 million in the US in five years time. CE approval for Europe opens up the second- largest market for prostate-cancer treatment next to the American market, where FDA approval has already been given. Palladium has an very short half-life and so it needs a short supply route to the customer. As a European manufacturer of palladium seeds, Eckert & Ziegler enjoys an excellent location edge. Every year there are 100,000 new cases of prostate cancer in Europe. Treatment with low-radiation seeds, called short-distance radiotherapy, is winning favor over conventional treatment methods thanks to its fewer side effects. The Board of Directors For further information please contact: Karolin Riehle Investor Relations Eckert & Ziegler AG Robert-Rössle-Str. 10 D-13125 Berlin Tel.: (+ 49 30) 94 10 84 - 138 Fax: (+ 49 30) 94 10 84 - 112 http://www.ezag.de End ----------------------------------------------------- Internet: http://recherche.newsaktuell.de Original-Content von: Eckert & Ziegler Strahlen und Medizintechnik AG, übermittelt durch news aktuell

Themen in dieser Meldung


Das könnte Sie auch interessieren: